Observational studyEmergency medicine Australasia : EMA2026
Toxicological and Clinical Characteristics of Fatal Cases in the Emerging Drugs Network of Australia-Victoria (EDNAV) Clinical Registry 2020-2025.
Observational study in Emergency medicine Australasia : EMA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThe objective of this study is to characterise the analytical toxicology findings and clinical features of fatal cases recorded in the Emerging Drugs Network of Australia-Victoria (EDNAV) clinical registry.
methodsEDNAV is a state-wide toxicosurveillance system capturing de-identified demographic, clinical and analytical data from ED presentations with illicit drug-related toxicity. Venous blood samples are screened for illicit, pharmaceutical and novel psychoactive substances (NPS) using liquid chromatography-quadrupole time-of-flight mass spectrometry. We conducted a retrospective observational case series of fatal registry cases recorded between September 2020 and December 2025.
resultsForty-six fatal cases were identified (0.9% of 5026 EDNAV cases). Most patients were male (89%) with a median age of 33 years. Out-of-hospital cardiac arrest occurred in 67% of cases. Polysubstance exposure predominated (91%), with a median of three substances detected per case. Mixed stimulant-sedative patterns were most common (64%), followed by opioid-benzodiazepine (19%) and stimulant-only (7%). The most frequent individual detections were methamphetamine (54%), heroin (52%), diazepam (37%), cocaine (20%) and MDMA (17%). NPS accounted for 7.8% of detections, were never identified in isolation and were predominantly novel benzodiazepines (80%). Hypoxic brain injury was the most common terminal complication (72%).
conclusionFatal cases were characterised by near-universal polysubstance detections, with methamphetamine and heroin the most frequent individual detections. Most deaths occurred out of hospital, with many patients presenting with irreversible hypoxic brain injury. NPS were rare and co-occurred with traditional illicit substances. Community-based interventions including bystander resuscitation, early emergency service activation and take-home-naloxone represent the highest-yield strategies to reduce mortality from illicit substance use in Victoria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.